GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inogen Inc (NAS:INGN) » Definitions » Debt-to-Equity

Inogen (Inogen) Debt-to-Equity : 0.11 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Inogen Debt-to-Equity?

Inogen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.7 Mil. Inogen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18.3 Mil. Inogen's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $204.8 Mil. Inogen's debt to equity for the quarter that ended in Dec. 2023 was 0.11.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Inogen's Debt-to-Equity or its related term are showing as below:

INGN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.03   Max: 0.11
Current: 0.11

During the past 13 years, the highest Debt-to-Equity Ratio of Inogen was 0.11. The lowest was 0.00. And the median was 0.03.

INGN's Debt-to-Equity is ranked better than
65.73% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs INGN: 0.11

Inogen Debt-to-Equity Historical Data

The historical data trend for Inogen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inogen Debt-to-Equity Chart

Inogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 0.07 0.08 0.11

Inogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.08 0.10 0.11

Competitive Comparison of Inogen's Debt-to-Equity

For the Medical Devices subindustry, Inogen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inogen's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inogen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Inogen's Debt-to-Equity falls into.



Inogen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Inogen's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Inogen's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inogen  (NAS:INGN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Inogen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Inogen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Inogen (Inogen) Business Description

Traded in Other Exchanges
Address
301 Coromar Drive, Goleta, CA, USA, 93117
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, Inogen sells its products through distributors or large gas companies and home oxygen providers. Inogen generates the majority of its revenue in the United States.
Executives
Thomas A. West director C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Stanislav Glezer officer: EVP, Chief Medical Officer C/O INOGEN, INC., 326 BOLLAY DRIVE., GOLETA CA 93117
Jason Somer officer: EVP, Gen. Counsel & Secretary C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Glenn S Boehnlein director 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Mary Kay Ladone director 130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601
Kevin M King director C/O AFFYMETRIX, INC., 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Kristin A. Caltrider officer: EVP, CFO and Treasurer C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Anderson Ray Benjamin M director 1100 NORTH WASHINGTON STREET, DELPHI IN 46923
Michael K. Sergesketter officer: EVP, CFO and Treasurer 301 COROMAR DRIVE, GOLETA CA 93117
Raymond Huggenberger director, officer: See Remarks 326 BOLLAY DRIVE, GOLETA CA 93117
Alison Bauerlein officer: See Remarks 326 BOLLAY DRIVE, GOLETA CA 93117
Brenton Taylor officer: Vice President, Engineering 326 BOLLAY DRIVE, GOLETA CA 93117
Elizabeth Mora director C/O MKS INSTRUMENTS, INC., 2 TECH DRIVE, SUITE 201, ANDOVER MA 01810
George J Parr director BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Byron Myers officer: Vice President, Marketing 326 BOLLAY DRIVE, GOLETA CA 93117